08 December 2022 – PLC has supported clinical development and regulatory filings for both Neurelis and ARS Pharmaceuticals throughout their drug product development phases and would like to congratulate ARS Pharmaceuticals on their Epinephrine nasal spray New Drug Application (NDA) acceptance by the US FDA.
NEURELIS CONGRATULATES INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, FOR FDA ACCEPTANCE OF INTRANASAL EPINEPHRINE NDA
- neffy® (epinephrine nasal spray), is developed with Neurelis’ proprietary Intravail® Absorption-Enhancing Technology
